Cancer cells are remarkably adaptable, often finding ways to survive even when critical repair systems within their DNA break down. Now, researchers at Scripps Research have uncovered a surprising strategy some cancer cells employ: a reliance on a less precise, “emergency” DNA repair mechanism called break-induced replication (BIR). This discovery, published in Cell Reports, not only illuminates how these cells persist but also suggests a potential recent avenue for targeted cancer therapies.
The health of our cells hinges on the integrity of their DNA. Constant attacks from within and without cause damage and one of the most dangerous forms is a double-strand break – essentially a complete severing of the DNA helix. Normally, cells have highly accurate systems to mend these breaks. But when those systems falter, cells can fall back on BIR, a more rudimentary process that, while allowing survival, introduces a higher risk of errors. Understanding how and when this backup system is activated is proving crucial in the fight against cancer, particularly in tumors that have become dependent on it.
The Role of R-Loops and SETX in DNA Stability
The Scripps Research team’s work centers on a protein called senataxin (SETX), a helicase responsible for untangling genetic material, including structures known as R-loops. These R-loops form when RNA doesn’t fully separate from the DNA strand it was copied from, leaving a vulnerable, exposed section of DNA. Research has shown that R-loops are essential for normal cell function, but their accumulation can lead to genomic instability – a hallmark of cancer.
“R-loops are important for many different cell functions, but they must be tightly controlled,” explains Xiaohua Wu, a professor at Scripps Research and senior author of the study. “If they aren’t properly regulated, they can accumulate to harmful levels and cause genome instability.” Interestingly, changes in the SETX gene are already linked to rare neurological disorders like ataxia and certain forms of amyotrophic lateral sclerosis (ALS), as well as some uterine, skin, and breast cancers. This connection prompted Wu’s team to investigate how cancer cells cope when SETX is missing or defective and R-loops build up.
How Cancer Cells Activate an Emergency Repair Pathway
The researchers focused on cells lacking SETX, observing a significant increase in R-loop levels. When double-strand breaks occurred in these cells, they noticed an unexpectedly robust response. “We were surprised but excited to find that the cell turns on an emergency DNA repair mechanism called break-induced replication (BIR),” Wu said. BIR isn’t the cell’s first choice for repair. It’s typically used to rescue stalled DNA replication or as a last resort for double-strand breaks. Instead of precise fixes, BIR essentially copies large stretches of DNA to reconnect broken pieces, a faster but less accurate method.
The team discovered that without SETX, R-loops accumulate directly at the sites of DNA breaks. This buildup disrupts the usual signals that guide DNA repair. The broken DNA ends are then excessively trimmed, exposing long strands of single-stranded DNA. This exposed DNA attracts the machinery needed for BIR, including a helicase called PIF1, which is essential for the process to start. The combination of exposed DNA and PIF1 effectively triggers the BIR repair pathway.
A Vulnerability in Cancer’s Survival Strategy
While BIR allows SETX-deficient cells to survive, it comes at a cost. Over time, these cells become reliant on BIR to repair DNA damage. Crucially, the researchers found that blocking this repair route leads to cell death. This phenomenon, known as synthetic lethality, is already exploited in some targeted cancer treatments, where a weakness specific to cancer cells is targeted without harming healthy cells.
Wu’s team identified three BIR-related proteins – PIF1, RAD52, and XPF – that SETX-deficient cells depend on heavily. “What’s important is that these aren’t essential in normal cells, which means we could selectively kill SETX-deficient tumors,” Wu explained. This selective targeting is the core of the potential therapeutic strategy.
From Lab Discovery to Potential Therapies
The research team is now focused on developing ways to inhibit these BIR factors, aiming to find compounds that are both effective and have minimal toxicity. They are also working to identify which cancers accumulate the highest levels of R-loops and under what conditions, to pinpoint the tumors most likely to respond to BIR-targeted therapies. While SETX deficiency is relatively rare, the buildup of R-loops can occur in a wider range of cancers through other mechanisms, such as oncogene activation or hormone signaling, like estrogen in certain breast cancers. This suggests the approach could have broader applicability.
The path to clinical application is still long, Wu cautions. Though, the identification of this vulnerability in cancer cells offers a promising new direction for research and potential treatment development. The team’s next steps involve further refining their understanding of the interplay between R-loops, SETX, and BIR, and identifying the most effective and safe ways to disrupt this emergency repair pathway in cancer cells.
This research was supported by the National Institutes of Health (grants GM141868, CA294646, CA244912 and CA187052).
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this research? Share your comments below, and please consider sharing this article with your network.
